Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model

Hepatology

Volumn 49, Issue 5, 2009, Pages 1483-1491

  Kamili, Saleem ^a   Sozzi, Vitini ^b   Thompson, Geoff ^b   Campbell, Katie ^c   Walker, Christopher M ^c   Locarnini, Stephen ^b   Krawczynski, Krzysztof ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS A VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA; ENGERIX-B; HEPATITIS B VACCINE; P PROTEIN, HEPATITIS B VIRUS; POL PROTEIN; RECOMBINANT VACCINE; RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CELLULAR IMMUNITY; CHIMPANZEE; CLONING; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; POINT MUTATION; PRIORITY JOURNAL; SEROCONVERSION; SERODIAGNOSIS; SITE DIRECTED MUTAGENESIS; STRUCTURAL GENE; TISSUE CULTURE; VACCINATION; VIRUS ENVELOPE; VIRUS MUTANT; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE; WILD TYPE; ANIMAL; DRUG EFFECT; EVALUATION; GENETICS; IMMUNOLOGY; MUTATION; PAN TROGLODYTES;

ANIMALS; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; MALE; MUTATION; PAN TROGLODYTES; RNA-DIRECTED DNA POLYMERASE; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 66149125213     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22796     Document Type: Article

References (25)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
2. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132:1574-1585.
3. Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. HEPATOLOGY 1999;29:230-237.
4. Mutimer D, Pillay D, Cook P, Ratcliffe D, O'Donnell K, Dowling D, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000;181:713-716.
5. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002;16:131-133.
6. Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994;169:1374-1376.
7. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance. HEPATOLOGY 1998;27: 294-297.
8. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313.
9. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002;68:319-327.
10. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, et al. Loss of the common "a" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992;90:2543-2547.
11. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336: 325-329.
12. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern? Vaccine 1999;17:973-978.
13. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003;38:506-510.
14. Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health? J Hepatol 2003;38:526-528.
15. Locarnini SA, Ferris AA, Stott AC, Gust ID. The relationship between a 27-nm virus-like particle and hepatitis A as demonstrated by immune electron microscopy. Intervirology 1974;4:110-118.
16. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 2001;19:3912-3918.
17. Tabor E, Purcell RH, London WT, Gerety RJ. Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers. J Infect Dis 1983;147:531-534.
18. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997;175:511-523.
19. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet 1988;2:1132-1133.
20. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and subtype cross-protection. N Engl J Med 1982;307:1481-1486.
21. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-1051.
22. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000;43:71-76.
23. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001;64:312-319.
24. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
25. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.